To our knowledge, EGR3 has not previously been investigated in gliomas, and our findings raise new questions about the role of EGR3 in GBM biology; the results indicate that EGR3 may be implicated in GBM cell migration and possibly also chemoresistance – two main features associated with treatment resistance and poor patient prognosis. This evidence concerns the gene EGR3 and glioma.